بدائل البحث:
largest decrease » largest decreases (توسيع البحث), larger decrease (توسيع البحث), marked decrease (توسيع البحث)
large increase » large increases (توسيع البحث), marked increase (توسيع البحث)
a largest » _ largest (توسيع البحث), a large (توسيع البحث), a latest (توسيع البحث)
b large » _ large (توسيع البحث), a large (توسيع البحث), i large (توسيع البحث)
largest decrease » largest decreases (توسيع البحث), larger decrease (توسيع البحث), marked decrease (توسيع البحث)
large increase » large increases (توسيع البحث), marked increase (توسيع البحث)
a largest » _ largest (توسيع البحث), a large (توسيع البحث), a latest (توسيع البحث)
b large » _ large (توسيع البحث), a large (توسيع البحث), i large (توسيع البحث)
-
141
-
142
-
143
A Mitochondria-Targeting SIRT3 Inhibitor with Activity against Diffuse Large B Cell Lymphoma
منشور في 2024"…Diffuse large B-cell lymphomas (DLBCLs) are heterogeneous cancers that still require better and less toxic treatments. …"
-
144
-
145
US cost-effectiveness analysis of polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma
منشور في 2023"…<p>We evaluated the pharmacoeconomic value of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) in previously untreated diffuse large B-cell lymphoma (DLBCL) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP).…"
-
146
-
147
-
148
-
149
-
150
-
151
-
152
-
153
-
154
Table_1_Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell Lymphoma.xlsx
منشور في 2021"…<p>Primary refractory/relapsed diffuse large B-cell lymphoma (rrDLBCL) is an unresolved issue for DLBCL treatment and new treatments to overcome resistance is required. …"
-
155
-
156
-
157
-
158
-
159
-
160